Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9569303 | 0.99 | TPSAB1 (0.35) | TPSAB1TPSD1TPSG1MAPTMEN1 | |
| SCHEMBL5982461 | 0.80 | GLA (0.43) | TPSAB1TPSD1TPSG1POLBALDH1A1 | |
| SCHEMBL5983070 | 0.79 | HPGD (0.45) | TPSAB1TPSD1TPSG1POLBALDH1A1 | |
| SCHEMBL5982386 | 0.79 | HPGD (0.45) | TPSAB1TPSD1TPSG1POLBALDH1A1 | |
| SCHEMBL5982410 | 0.79 | HPGD (0.45) | TPSAB1TPSD1TPSG1POLBALDH1A1 | |
| SCHEMBL9136130 | 0.77 | HPGD (0.32) | MAPTMEN1POLBKMT2AALDH1A1 | |
| SCHEMBL5982713 | 0.77 | HPGD (0.32) | MAPTMEN1POLBKMT2AALDH1A1 | |
| SCHEMBL5983036 | 0.76 | LMNA (0.47) | POLBALDH1A1LMNAHPGD | |
| SCHEMBL5982861 | 0.75 | TPSAB1 (0.36) | TPSAB1TPSD1TPSG1MAPTALDH1A1 | |
| SCHEMBL5982318 | 0.74 | TPSAB1 (0.38) | TPSAB1TPSD1TPSG1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
| EP-1232166-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | Pharmasset Limited (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001034618-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | PHARMASSET LIMITED (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | TPSAB1 4804/4885TPSD1 4208/4885TPSG1 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.